title: Palmitoylethanolamide effects on intraocular pressure after Nd:YAG laser iridotomy: an experimental clinical study.
abstract: OBJECTIVE
  The purpose of this article was to evaluate whether the anti-inflammatory agent palmitoylethanolamide (PEA) can counteract the increase of intraocular pressure (IOP) that may occur after neodymium-doped: yttrium aluminum garnet (Nd:YAG) laser iridotomy.
  
  
  METHODS
  Fifteen patients underwent bilateral laser iridotomy (Visulas YAG III Laser; Zeiss) for the prevention of primary closed-angle glaucoma. The IOP was measured at the beginning of the study (t-1), after 15 days of pretreatment with placebo or PEA (t0), and at 15, 30, and 120 min after the iridotomy (t1, t2, t3). The pretreatment consisted of 2 tablets of placebo or PEA per day for 15 days.
  
  
  RESULTS
  The t-test did not show a significant difference between the preoperative mean values of IOP t-1 and t0 in both the pretreatments. Analysis of variance/Tukey's test pointed out a significant increase of the postoperative IOP values in placebo pretreated patients (P≤0.05), but not in those who were pretreated with PEA. The trend analysis confirmed the significant positive trend in placebo pretreatment. The parallelism test between the 2 regressions showed a significant difference for the slopes (P=0.022) and not for the intercepts (P=0.520).
  
  
  CONCLUSIONS
  PEA can counteract the increase of IOP that occurs after iridotomy. It is likely that PEA controls the inflammatory process after iridotomy.
authors.affiliation: Department of Cardiovascular, Respiratory, Nephrology and Geriatric Sciences, Centre Glaucoma and Ocular Electrophysiology, Sapienza University of Rome, Rome, Italy.
authors.forename: Nicola
authors.initials: N
authors.lastname: Pescosolido
authors.forename: Aloisa
authors.initials: A
authors.lastname: Librando
authors.forename: Marta
authors.initials: M
authors.lastname: Puzzono
authors.forename: Marcella
authors.initials: M
authors.lastname: Nebbioso
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000577:Amides; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D063388:Endocannabinoids; D004983:Ethanolamines; D005260:Female; D015812:Glaucoma, Angle-Closure / Q000517:prevention & control / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D007498:Iris / Q000601:surgery*; D053685:Laser Therapy / Q000009:adverse effects / Q000295:instrumentation; D053844:Lasers, Solid-State; D008297:Male; D008875:Middle Aged; D010169:Palmitic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D000577:Amides; D000894:Anti-Inflammatory Agents, Non-Steroidal; D063388:Endocannabinoids; D004983:Ethanolamines; D010169:Palmitic Acids; C005958:palmidrol